CTOs on the Move

DBV Technologies

www.dbv-technologies.com

 
DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Pascal Wotling
Chief Technical Operations Officer Profile

Similar Companies

Brightseed

Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.

Argene SA

Argene SA is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CerFlux

CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.